These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 33933117

  • 1. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
    West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE.
    Mol Neurodegener; 2021 May 01; 16(1):30. PubMed ID: 33933117
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H, Klafki HW, Bauer C, Schuchhardt J, Hüttenrauch M, Stazi M, Bouter C, Wirths O, Vogelgsang J, Wiltfang J.
    Alzheimers Res Ther; 2018 Dec 08; 10(1):121. PubMed ID: 30526652
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
    Pascual-Lucas M, Allué JA, Sarasa L, Fandos N, Castillo S, Terencio J, Sarasa M, Tartari JP, Sanabria Á, Tárraga L, Ruíz A, Marquié M, Seo SW, Jang H, Boada M, FACEHBI study group.
    Alzheimers Res Ther; 2023 Jan 05; 15(1):2. PubMed ID: 36604729
    [Abstract] [Full Text] [Related]

  • 10. Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.
    Rippon B, Palta P, Tahmi M, Sherwood G, Soto L, Cespedes S, Mesen Y, He H, Laing K, Moreno H, Teresi J, Razlighi Q, Brickman AM, Zetterberg H, Luchsinger JA.
    J Alzheimers Dis; 2022 Jan 05; 87(3):1229-1238. PubMed ID: 35466933
    [Abstract] [Full Text] [Related]

  • 11. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
    Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, Lee DH, Ye BS, Kim JH, Kim EJ, Park KH, Han HJ, Jeong JH, Choi SH, Park SA.
    J Alzheimers Dis; 2015 Jan 05; 48(4):1043-50. PubMed ID: 26444752
    [Abstract] [Full Text] [Related]

  • 12. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
    Pérez-Grijalba V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, Guillen F, Monleón I, San-José I, Martínez-Lage P, Munuera J, Hernández I, Buendía M, Sotolongo-Grau O, Alegret M, Ruiz A, Tárraga L, Boada M, Sarasa M, AB255 Study Group.
    Alzheimers Res Ther; 2019 Dec 01; 11(1):96. PubMed ID: 31787105
    [Abstract] [Full Text] [Related]

  • 13. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 01; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 14. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
    Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C, Bateman RJ, Holtzman DM, Irizarry M, Verbel D, Sachdev P, Ito S, Contois J, Yarasheski KE, Braunstein JB, Verghese PB, West T.
    Alzheimers Dement; 2024 May 01; 20(5):3179-3192. PubMed ID: 38491912
    [Abstract] [Full Text] [Related]

  • 15. Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity.
    Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, Baratta M, Kolb HC, Dobler I, Mordashova Y, Saad ZS, Raunig DL, Spanakis EM, Li Y, Schindler SE, Ferber K, Rubel CE, Martone RL, Weber CJ, Edelmayer RM, Meyers EA, Bollinger JG, Rosenbaugh EG, Potter WZ, Alzheimer's Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer's Disease Project Team.
    Alzheimers Dement; 2023 Mar 01; 19(3):956-966. PubMed ID: 35820077
    [Abstract] [Full Text] [Related]

  • 16. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, Kim SE, Lee BS, Kim GJ, Yu JS, Lim K, Kang SM, Park YH, Youn YC, An SSA, Kim S.
    Alzheimers Res Ther; 2017 Dec 15; 9(1):98. PubMed ID: 29246249
    [Abstract] [Full Text] [Related]

  • 17. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
    Udeh-Momoh C, Zheng B, Sandebring-Matton A, Novak G, Kivipelto M, Jönsson L, Middleton L.
    J Prev Alzheimers Dis; 2022 Dec 15; 9(1):12-21. PubMed ID: 35098969
    [Abstract] [Full Text] [Related]

  • 18. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.
    JAMA Neurol; 2014 Oct 15; 71(10):1282-9. PubMed ID: 25155658
    [Abstract] [Full Text] [Related]

  • 19. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease.
    Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali LK, Llano DA, Zhou J, Reyderman L, Hampel H, Kramer LD, Dhadda S, Irizarry MC.
    Alzheimers Dement; 2024 Aug 15; 20(8):5617-5628. PubMed ID: 38940656
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.